Posters

Myopia and astigmatism correction with Artiflex® toric IOL: our experience

Poster Details

First Author: P.Coelho PORTUGAL

Co Author(s):    T. Maio   J. Moreira   F. Sampaio   P. Rodrigues   R. Resende        

Abstract Details

Purpose:

The aim of this study was to assess the refractive, functional and safety outcomes of the Artiflex® toric intra-ocular lens.

Setting:

Department of Ophthalmology Hospital Pedro Hispano, Matosinhos, Portugal

Methods:

This retrospective analysis included 35 eyes of 22 myopic patients submitted to toric Artiflex® iris claw IOL implantation, with at least 6 months of follow-up and no previous history of ocular surgery. Mean patient age was 35,2 ±7 years and the follow-up time was 19,5 ± 7,5 months. Pre and pos operative data collected were uncorrected visual acuity (UCVA), best-corrected visual acuity (BCVA), topography parameters and endothelial cell density.

Results:

Pre operative BCVA was 0,095 ±0,14logMar, with a mean sphere, cilinder and spherical equivalent of -8,26 ± 2,8D; -2,23 ± 1,2D and -9,37 ± 2,9D respectively. At the follow-up time the UCVA was 0,049 ±0,09 logMar, and it was not inferior to the pre operative BCVA (p=0,170). The residual spherical equivalent was 0,06 ±0,4 logMar. The percentage of the eyes with a pos operative sphere between ±0,5D was 94%, with 76% of the patients reaching a cilinder of ±0,5D. The decrease of endotelial cells density was statistical significant (mean decrease of 97 ±147 cells (3,5%); p=0,001).

Conclusions:

Artiflex® toric IOL evidenced very satisfactory refractive results in patients with moderate myopia and astigmatism.Financial Disclosure: none

Financial Disclosure:

NONE